It is also important to have a better understanding of the molecular mechanisms by which IDH mutations promote the pathogenesis of AML, which will enable the search for new molecular targets that could improve the effectiveness of mIDH inhibitor therapy. The gene discussed is IDH1; the disease is acute myeloid leukemia.